Study summary

Trastuzumab deruxtecan beat standard second-line treatment for HER2-positive cancer

DESTINY-Gastric04 trial · 494 people, phase 3 · Published May 2025, New England Journal of Medicine

30%lower risk of death than ramucirumab plus paclitaxel

What was tested

Trastuzumab deruxtecan, an antibody-drug conjugate, against ramucirumab plus paclitaxel, after first treatment for HER2-positive stomach or junction cancer.

What they found

Risk of death was 30% lower (hazard ratio 0.70).
Time before growth was also longer (hazard ratio 0.74).

What it means

Confirms trastuzumab deruxtecan as the second-line standard for HER2-positive disease.

N Engl J Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.